

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 09/780,566

Filing Date February 12, 2001

First Named Inventor Bert Vogelstein et al

Group Art Unit 1642

Examiner Name Misook Yu


Attorney Docket Number 01107.00092

JAN 21 2003
PATENT & TRADEMARK OFFICE
O I P
JC
RECEIVED
TECH CENTER 1600
JAN 23 2003
16002900

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response with Exhibits A-J	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		Remarks
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Michelle L. Holmes-Son, Reg. No.47,660
Signature	
Date	January 21, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name		Date
Signature		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

25-1-2603
PATENT

w/attach

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Bert Vogelstein, *et. al.*

Serial No. 09/780,566

Filed: February 12, 2001

For: CDK4 IS A TARGET OF c-MYC



) Group Art Unit: 1642
)
)
Examiner: Misook Yu
)
Docket No. 01107.00092
)

RECEIVED
JAN 23 2003
TECH CENTER 1600/2900

AMENDMENT AND RESPONSE TO OFFICE ACTION

Assistant Director for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed October 18, 2002, applicants request entry of the following amendments and reconsideration of the patentability of the claims. Claims 25-32 are pending in the application and stand rejected. No fees are believed necessary to make this response timely filed. If any fees are deemed necessary please charge our Deposit Account Number 19-0733.

Appendix 1 is a version of amended claims, with markings to show changes made.

IN THE CLAIMS:

Please amend claim 25.

25. (Twice Amended) A method of screening compounds to identify as candidate agents those which have anti-cancer activity, comprising the steps of:

contacting a cell which has a genetic alteration which dysregulates *c-MYC* expression with a test compound, wherein the genetic alteration causes *c-MYC* overexpression;